Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting.
van Halsema
Clare L
CL
London School of Hygiene and Tropical Medicine, London, UK. clare.vanhalsema@lshtm.ac.uk
Fielding
Katherine L
KL
Chihota
Violet N
VN
Russell
Elizabeth C
EC
Lewis
James J C
JJ
Churchyard
Gavin J
GJ
Grant
Alison D
AD
D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000453:epidemiology*; D015497:HIV-1; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D008297:Male; D015995:Prevalence; D013019:South Africa / Q000453:epidemiology; D016896:Treatment Outcome; D014376:Tuberculosis / Q000453:epidemiology / Q000517:prevention & control*
D000995:Antitubercular Agents; D007538:Isoniazid